Urology Medical News about Detrusor Overactivity

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection
European Urology, 09/18/09

Liu HT et al. – Urinary nerve growth factor (NGF) level is a promising biomarker for the diagnosis of overactive bladder. Measurement of urine NGF levels may serve as a useful objective test to evaluate idiopathic detrusor overactivity and neuropathic detrusor overactivity treatment outcome such as with botulinum toxin A treatment.

<< Previous
Large-scale Real-time Reverse Transcription-PCR Approach of...

Next >>
A Prospective Randomised Trial of Extended Core Prostate Biopsy...

Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: A retrospective study of seven cases
Journal of Pediatric Urology, 11/17/09 Relevance Score: 67%

Bladder Function After Total Urogenital Mobilization for Persistent Cloaca
The Journal of Urology, 10/30/09 Relevance Score: 66%

Second-line therapy of idiopathic detrusor overactivity
Der Urologe, 10/30/09 Relevance Score: 65%

Objective differences between overactive bladder patients with and without urodynamically proven detrusor overactivity
International Urogynecology Journal, 11/17/09 Relevance Score: 64%

Is ultrasound estimation of bladder weight a useful tool in the assessment of patients with lower urinary tract symptoms
International Urogynecology Journal, 10/07/09 Relevance Score: 64%